In light of the relatively high mutation rate of KIT in cutaneous melanoma and since BRAF, KIT, and NRAS mutations appear to be mutually exclusive, the screening of KIT mutations, at least in exons 9/11/13, is suggested in BRAF/NRAS double-wild-type melanoma patients (31, 34, 45, 46). The gene discussed is KIT; the disease is cutaneous melanoma.